Credit: Courtesy of mes°
Celebrity beauty used to mean a famous face and a contract manufacturer. Mes° starts with a biotech company instead, and the lab is the real headline.
What's happening
Jennifer Lawrence launches Mes° (pronounced "mess") on 27 October, a haircare range the brand calls "biodesigned". She teased it on Instagram on 16 October, and Puck reported on 21 October that the range was engineered with Arcaea, a Boston biotech company founded in 2021 by MIT graduate Jasmina Aganovic. Arcaea raised a reported $78 million Series A, with investors including Givaudan, Chanel and Bill Gates's Cascade Investment. Olaplex took a minority stake in 2022. Products, prices, retailers and deal terms had not been disclosed at the time of writing (Cosmetics Business).
Why now: fame stopped being enough
A decade of celebrity launches has taught shoppers that a famous name buys a launch week, not a reorder. By month three, people repurchase based on results and price. A named science partner gives a brand something a rival cannot copy by signing a different actress.
The lab is the new entry ticket
For Lawrence, a funded lab is borrowed credibility: she does not have to convince anyone that she can formulate. For Arcaea, she is a borrowed distribution, a consumer audience that a B2B biotech firm cannot buy. Both sides are paying for what they lack.
The problem: a word is not a result
"Biodesigned" has no consumer meaning yet. It will either become shorthand or turn into jargon, and shoppers will not decode it for you. Expect journalists, dermatologists and trichologists to ask what is biodesigned, how, and compared to what. If the brand does not publish the proof first, critics will frame it. There is a structural risk too: a brand built on a face and a lab is exposed if either partner wobbles, and the deal terms are unknown.
Our verdict
Pairing a funded lab with a celebrity is the most interesting new structure in celebrity beauty in years, and it only works if "biodesigned" turns into a visible result within weeks. The winners will treat the star as the distribution and the science as the product. The rest will have bought a very expensive adjective.
→ Read the Full Article
